报价延迟最少15分钟:2026/03/28 20:33 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.01 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.80/0.51
|
|
企业价值
422.77M
|
| 资产负债 |
|
每股账面净值
-0.36
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
297.18M
|
|
每股收益
2.85
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia. |
